Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).

Authors

Matt D. Galsky

Icahn School of Medicine at Mount Sinai, New York, NY

Matt D. Galsky , Enrique Grande , Andrea Necchi , Michael Zach Koontz , Gopa Iyer , Matthew T Campbell , Alexandra Drakaki , Yohann Loriot , Kevin M. Sokolowski , Wei Zhang , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.

First Author: Xinan Sheng

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).

First Author: Guru P. Sonpavde

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.

First Author: Brian M. Slomovitz

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma.

First Author: Xinan Sheng